An observational study in Gestational Diabetes Mellitus (GDM) and Pregnancy, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Medical University of Graz · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.
Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 10th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–45 · Women only
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Sites in Austria, Italy
Ages 35+ · Women only
Medical University of Graz · Sites in Austria
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 175 across 290 observational studies indexed under Diabetes, Gestational.
Median enrollment 67 across the 5 interventional studies, 275 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 3 most frequent:
Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.
Medical University of Graz has 3 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes, Gestational with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07685015Medical University of ViennaThe Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes, Gestational with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gestational diabetes mellitus (GDM) is a common pregnancy complication characterized by impaired glucose metabolism and increased insulin resistance. GDM is associated with adverse pregnancy outcomes and an increased long-term risk of metabolic and cardiovascular disease for both mother and offspring.
This prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with GDM. Pregnant women with a positive 75 g oral glucose tolerance test (OGTT) between gestational weeks 24 and 28 will be recruited after diagnosis and followed through late pregnancy, delivery, and early postpartum.
Participants will undergo two study visits during pregnancy, sample collection at delivery, and one postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of GDM pregnancies.
Data and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of GDM-related changes.
Gestational diabetes mellitus (GDM) develops when physiological insulin resistance during pregnancy exceeds adaptive capacity, resulting in impaired glucose regulation. GDM is associated with increased perinatal morbidity and elevated long-term risk for metabolic and cardiovascular disease in both mothers and offspring. Despite its clinical relevance, the biological mechanisms underlying GDM and its long-term consequences are incompletely understood.
This prospective, monocentric observational cohort study is designed to establish a well-characterized longitudinal pregnancy and birth cohort of women diagnosed with GDM. The primary objective is to collect clinical data and biological samples across pregnancy, delivery, and early postpartum to support detailed phenotyping of GDM pregnancies and early-life outcomes.
Approximately 100 pregnant women with a confirmed diagnosis of GDM will be recruited per year at the Department of Obstetrics and Gynecology. Eligible participants are women aged 18 years or older with an ongoing pregnancy prior to gestational week 32 and a positive 75 g OGTT performed as part of routine clinical care. Women with major fetal anomalies are excluded.
Study participation includes four time points: 1.) a visit following GDM diagnosis (approximately gestational weeks 26-30), 2.) a late pregnancy visit (approximately weeks 34-37), 3.) sample and clinical data collection at delivery, and 4) a postpartum follow-up visit 8-12 weeks after birth.
At each study visit, standardized clinical assessments, physical measurements, and questionnaire-based information will be collected. Maternal assessments include anthropometry, body composition, blood pressure, and selected non-invasive cardiovascular and metabolic measurements. Fetal growth is assessed by routine obstetric ultrasound. At delivery, perinatal samples such as placenta, umbilical cord, and cord blood are collected. Postnatal assessments include maternal and infant anthropometry and selected cardiovascular measurements where applicable.
Biological samples collected longitudinally may include blood, urine, saliva, vaginal swabs, breast milk, placental tissue, umbilical cord tissue, and umbilical cord blood. Samples are processed and stored in a biobank for future analyses following separate ethical approvals. Clinical metadata include pregnancy outcomes, GDM treatment, delivery characteristics, and neonatal outcomes.
Lifestyle and behavioral factors, including nutrition and physical activity, are assessed using standardized questionnaires. Data are pseudonymized and handled in accordance with applicable data protection regulations.
This study is designed as a cohort and sample collection platform.
For contextual comparison, data and biosamples from an existing longitudinal cohort of healthy pregnancies will be used where appropriate. Alignment of visit timing and data collection procedures allows comparative analyses between GDM and normoglycemic pregnancies.
The study population consists of pregnant women diagnosed with gestational diabetes mellitus (GDM) based on a positive 75 g oral glucose tolerance test performed as part of routine clinical care between gestational weeks 24 and 28. Participants are recruited after diagnosis at a tertiary care obstetric center and followed through late pregnancy, delivery, and early postpartum.
Eligible participants are adults aged 18 years or older with an ongoing singleton pregnancy prior to gestational week 32. Women with major fetal anomalies are excluded. In addition, a non-pregnant reference cohort of healthy adult males and non-pregnant females may be recruited for selected analyses to provide pregnancy- and sex-independent reference data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Maternal metabolic and cardiometabolic phenotype: Adiposity
Measured as fat mass and fat-free mass by air displacement plethysmography longitudinally after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Maternal metabolic and cardiometabolic phenotype: fasting glucose
Fasting blood glucose as measured in mg/mL from NaF blood tubes longitudinally after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Maternal metabolic and cardiometabolic phenotype: blood pressure
Resting systolic and diastolic blood pressure measured using standardized clinical procedures after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Maternal metabolic and cardiometabolic phenotype: cytokine profile
Serum cytokine will be analysed by multiplexing after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Maternal metabolic and cardiometabolic phenotype: lipid profile (triglycerides, phospholipids, free, fatty acids, HDL/LDL/total cholesterol)
Lipid profiles are measured after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Maternal metabolic and cardiometabolic phenotype: endothelial function
Endothelial function measured as pulse wave velocity using a Vicorder® after gestational diabetes diagnosis and during early postpartum follow-up.
Time frame: From study enrollment after GDM diagnosis (approximately gestational weeks 26-30) through 8-12 weeks postpartum.
Infant outcomes: adiposity
Measured as fat mass and fat-free mass by air displacement plethysmography (via PEAPOD)
Time frame: At birth and at 8-12 weeks postpartum.
Infant outcomes: Neonatal C-peptide in cord blood
Concentrations of C-peptide in cord blood serum
Time frame: At birth
Infant outcomes: Neonatal glucose in cord blood
Concentrations of glucose in cord blood serum
Time frame: At birth
Started Jun 2025 (actual). Primary completion is estimated for Jun 2030, 60 months after the start.
Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 60 months is above that.
Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.